Kairos Pharma Ltd. (NYSE American: KAPA) announced its participation in the DealFlow Discovery Conference scheduled for January 28-29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company's Chief Scientific Officer, Neil Bhowmick, will deliver a company presentation and conduct one-on-one meetings with investors during the event as Kairos continues advancing its clinical-stage oncology programs.
The conference participation comes as Kairos Pharma focuses on developing oncology therapeutics that utilize structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs in oncology treatment. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA.
The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies with significant growth potential. TinyGems is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers comprehensive corporate communications solutions, including access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release services, and social media distribution to millions of followers. For more information about TinyGems, visit https://www.TinyGems.com.
For investors and industry observers, Kairos Pharma's participation in the DealFlow Discovery Conference represents an opportunity to gain insight into the company's progress with its clinical programs. The conference serves as a platform for emerging companies to connect with potential investors and partners, which could accelerate development timelines and provide additional resources for clinical trials. The focus on overcoming drug resistance in cancer treatment addresses a critical challenge in oncology, where many patients experience relapse due to developed resistance to standard therapies.
The implications of Kairos Pharma's work extend beyond individual patient outcomes to potentially transform treatment paradigms for multiple cancer types. If successful, ENV-105 could enable existing cancer therapies to maintain effectiveness longer, reducing the need for constant development of entirely new treatment approaches. This approach represents a strategic shift in cancer research toward enhancing the durability of existing treatments rather than solely pursuing novel compounds.
For the broader oncology market, advancements in overcoming drug resistance could lead to more sustainable treatment regimens and potentially lower long-term healthcare costs associated with cancer care. The company's structural biology approach to addressing resistance mechanisms may also inform future research directions across the pharmaceutical industry, particularly in therapeutic areas where drug resistance presents significant challenges to treatment efficacy.
